Literature DB >> 1536850

Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix.

R Ishai-Michaeli1, C M Svahn, M Weber, T Chajek-Shaul, G Korner, H P Ekre, I Vlodavsky.   

Abstract

We have characterized the importance of size, sulfation, and anticoagulant activity of heparin in release of basic fibroblast growth factor (bFGF) from the subendothelial extracellular matrix (ECM) and the luminal surface of the vascular endothelium. For this purpose, 125I-bFGF was first incubated with ECM and confluent endothelial cell cultures, or administered as a bolus into the blood of rats, the immobilized 125I-bFGF was then subjected to release by various chemically modified species of heparin and size-homogeneous oligosaccharides derived from depolymerized heparin. Both totally desulfated and N-desulfated heparin failed to release the ECM-bound bFGF. Likewise, substitution of N-sulfate groups of heparin and low molecular weight heparin (fragmin) by acetyl or hexanoyl residues resulted in an almost complete inhibition of bFGF release by these polysaccharides. The presence of O-sulfate groups in heparin increased but was not critical for release of ECM-bound bFGF. Similar structural requirements were identified for release of 125I-bFGF bound to low-affinity sites on the surface of vascular endothelial cells. Oligosaccharides derived from depolymerized heparin and containing as little as 8-10 sugar units were, on a weight basis, equivalent to whole heparin in their ability to release bFGF from ECM. Low-sulfate oligosaccharides were less effective releasers of bFGF as compared to medium- and high-sulfate fractions of the same size oligosaccharides. Heparin fractions with high and low affinity to antithrombin III exhibited a similar high bFGF-releasing activity despite a 200-fold difference in their anticoagulant activities.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536850     DOI: 10.1021/bi00122a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding.

Authors:  Alisa Morss Clyne; Elazer R Edelman
Journal:  Cytotechnology       Date:  2009-07-29       Impact factor: 2.058

2.  Preactivation-based, one-pot combinatorial synthesis of heparin-like hexasaccharides for the analysis of heparin-protein interactions.

Authors:  Zhen Wang; Yongmei Xu; Bo Yang; Gopinath Tiruchinapally; Bin Sun; Renpeng Liu; Steven Dulaney; Jian Liu; Xuefei Huang
Journal:  Chemistry       Date:  2010-07-26       Impact factor: 5.236

3.  Correction of hypertension by normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats.

Authors:  P Cuevas; M García-Calvo; F Carceller; D Reimers; M Zazo; B Cuevas; I Muñoz-Willery; V Martínez-Coso; S Lamas; G Giménez-Gallego
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Unraveling the specificity of heparanase utilizing synthetic substrates.

Authors:  Sherket B Peterson; Jian Liu
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

5.  Fibroblast growth factor 2, heparin and suramin reduce epithelial ulcer development in experimental HSV-1 keratitis.

Authors:  P Rieck; J Denis; D Peters; C Hartmann; Y Pouliquen; Y Courtois
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-11       Impact factor: 3.117

Review 6.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

7.  G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.

Authors:  C A Stein; Sijian Wu; Anatoliy M Voskresenskiy; Jin-Feng Zhou; Joongho Shin; Paul Miller; Naira Souleimanian; Luba Benimetskaya
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

8.  Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

Authors:  R G Williams; S Chang; M R Comaratta; G Simoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

9.  Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate.

Authors:  A G Gambarini; C A Miyamoto; G A Lima; H B Nader; C P Dietrich
Journal:  Mol Cell Biochem       Date:  1993-07-21       Impact factor: 3.396

10.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition.

Authors:  E R Edelman; M A Nugent; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.